Back
Blueprint Medicines Stock Price Chart
The key to a $1.3T opportunity
This is a paid advertisement for Pacaso's Regulation A offering. Please read the offering circular and related risks at invest.pacaso.com.
Buy
52
BPMC
Blueprint Medicines
Last Price:
$99.38
Seasonality Move:
13.41%
7 Day Trial
ALL ACCESS PASS
$
7
FREE Copy of "2025 Gold Forecast: A Perfect Storm for Demand"
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report here-
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and BPMC is experiencing slight selling pressure.
Blueprint Medicines Price Chart Indicators
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 100.14 | Sell |
| 20-day SMA: | 92.11 | Buy |
| 50-day SMA: | 89.4 | Buy |
| 200-day SMA: | 93.79 | Buy |
| 8-day EMA: | 98.24 | Buy |
| 20-day EMA: | 94.25 | Buy |
| 50-day EMA: | 92.15 | Buy |
| 200-day EMA: | 92.83 | Buy |
Blueprint Medicines Technical Analysis Indicators
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 3.53 | Buy |
| Relative Strength Index (14 RSI): | 61.73 | Buy |
| Chaikin Money Flow: | -61922 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (81.79 - 97.99) | Buy |
| Bollinger Bands (100): | (84.89 - 103.87) | Buy |
Blueprint Medicines Technical Analysis
| Apr 30 | May 1 | May 2 | May 5 | May 6 | May 7 | May 8 | May 9 | May 12 | May 13 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr | May | |||||||||
| 30 | 01 | 02 | 05 | 06 | 07 | 08 | 09 | 12 | 13 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Technical Analysis for Blueprint Medicines Stock
Is Blueprint Medicines Stock a Buy?
-
Blueprint Medicines share price is 99.41 while BPMC 8-day simple moving average is 100.14, which is a Sell signal.
-
The stock price of BPMC is 99.41 while Blueprint Medicines 20-day SMA is 92.11, which makes it a Buy.
-
Blueprint Medicines 50-day simple moving average is 89.40 while BPMC share price is 99.41, making it a Buy technically.
-
BPMC stock price is 99.41 and Blueprint Medicines 200-day simple moving average is 93.79, creating a Buy signal.
BPMC Technical Analysis vs Fundamental Analysis
Buy
52
Blueprint Medicines (BPMC)
is a Buy
Is Blueprint Medicines a Buy or a Sell?
-
Blueprint Medicines stock is rated a BuyThe current Blueprint Medicines [BPMC] share price is $99.41. The Score for BPMC is 52, which is 4% above its historic median score of 50, and infers lower risk than normal.
Blueprint Medicines Stock Info
Market Cap:
6.4B
Price in USD:
99.41
Share Volume:
595.6K
Blueprint Medicines 52-Week Range
52-Week High:
121.90
52-Week Low:
73.04
Buy
52
Blueprint Medicines (BPMC)
is a Buy
Blueprint Medicines Share Price Forecast
-
What is the Blueprint Medicines stock price today?The Blueprint Medicines stock price is 99.41 USD today.
-
Will BPMC stock go up or go down?Blueprint Medicines> share price is forecast to RISE/FALL based on technical indicators
-
Is Blueprint Medicines overvalued?According to simple moving average, exponential moving average, oscillators, and other technical indicators, Blueprint Medicines is not overvalued.
Is Blueprint Medicines Stock a Buy?
-
Blueprint Medicines share price is 99.41 while BPMC 8-day exponential moving average is 98.24, which is a Buy signal.
-
The stock price of BPMC is 99.41 while Blueprint Medicines 20-day EMA is 94.25, which makes it a Buy.
-
Blueprint Medicines 50-day exponential moving average is 92.15 while BPMC share price is 99.41, making it a Buy technically.
-
BPMC stock price is 99.41 and Blueprint Medicines 200-day simple moving average is 92.83, creating a Buy signal.
Fundamental Analysis of Blueprint Medicines
Is Blueprint Medicines a good investment?
-
Analysts estimate an earnings increase this quarter of $0.67 per share, an increase next quarter of $0.33 per share, an increase this year of $0.60 per share, and an increase next year of $1.46 per share.
Technical Analysis of Blueprint Medicines
Should I short Blueprint Medicines stock?
-
BPMC Moving Average Covergence Divergence (MACD) indicator is 3.53, suggesting Blueprint Medicines is a Buy
-
Blueprint Medicines Relative Strength Index (RSI) is 61.73, which suggest Blueprint Medicines is overbought
-
The Bollinger Bands (25) for Blueprint Medicines is (81.79 - 97.99), which suggest Blueprint Medicines is a Buy
-
The Bollinger Bands (100) for Blueprint Medicines is (84.89 - 103.87), which suggest Blueprint Medicines is a Buy
* Blueprint Medicines stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.